Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Current Liabilities (2024 - 2025)

Prelude Therapeutics' Total Current Liabilities history spans 2 years, with the latest figure at $53.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 106.68% year-over-year to $53.0 million; the TTM value through Dec 2025 reached $53.0 million, up 106.68%, while the annual FY2025 figure was $53.0 million, 106.68% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $53.0 million at Prelude Therapeutics, up from $18.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $53.0 million in Q4 2025 and bottomed at $17.6 million in Q1 2024.